Pfizer Takes 45 Oncology Studies to ESMO 2025 Congress in Madrid Across Oral and Poster Sessions

Eleven oral presentations among 45 total oncology studies signals that Pfizer is carrying a substantive late-stage data burden into the ESMO Congress (October 23–27, Madrid), and for CDMOs and contract manufacturers tracking pipeline-to-plant transitions, the volume of readouts warrants close attention to which candidates may trigger near-term tech transfer or manufacturing scale-up discussions.

Pfizer confirmed the full slate of 45 presentations spans oral sessions and poster formats across the congress programme. Oral sessions, by convention, are reserved for data of higher clinical significance, making the 11 designated oral presentations the primary signal for late-stage advancement. Candidates reaching positive readouts at a congress of this scale typically accelerate commercial manufacturing planning within months of data disclosure.

For QA directors and regulatory affairs leads at CDMOs engaged in oncology, the ESMO data package carries direct operational relevance. Late-stage oncology assets moving toward BLA or NDA submission require validated manufacturing processes, stability data packages aligned with ICH Q1 requirements, and, where sterile injectables are involved, sterility assurance programmes consistent with 21 CFR Part 211. A positive Phase III readout at ESMO can compress the timeline between process validation completion and regulatory submission to under 18 months.

Pfizer has not publicly itemised all 45 study titles ahead of the congress, which is standard practice under embargo protocols. The breadth of the portfolio, 45 studies across a single congress, reflects the company's sustained investment in oncology following its acquisition of Seagen in 2023, which added antibody-drug conjugate (ADC) programmes requiring specialised high-potency manufacturing infrastructure.

Plant heads and manufacturing leads at organisations already engaged with Pfizer's oncology supply chain should treat the October readouts as a planning checkpoint: positive data from oral sessions may initiate or accelerate capacity reservation conversations before year-end.

Source: Media4Growth via Indian Pharma Post, 28 September 2026.